Sigma Planning’s Lineage Cell Therapeutics LCTX Stock Holding History
Bought
Maintained
Sold
Other funds holding LCTX
Sigma Planning's LCTX Position: Q3 2026 in Review
Sigma Planning opened a new position in Lineage Cell Therapeutics (LCTX) in Q3 2026: 10,115 shares worth $9.7K. The stake represents ﹤0.01% of the portfolio and ranks #1323 among its holdings.
109 funds tracked by Wall St. Rank hold LCTX as of Q3 2026.
- Sigma Planning held 10,115 shares of Lineage Cell Therapeutics worth $9.7K as of Q3 2026.
- Lineage Cell Therapeutics was a new Sigma Planning position in Q3 2026.
- Lineage Cell Therapeutics made up ﹤0.01% of Sigma Planning's portfolio in Q3 2026, its #1323 holding.
- 109 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2026.
Based on Sigma Planning's 13F filing for Q3 2026, filed 23 Oct 2026.